Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Karyopharm Therapeutics Inc
KPTI | US
8.77
USD-0.05
-0.57%
KPTI | US
About Karyopharm Therapeutics Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
06/03/2026
Close
8.77
Open
8.72
High
9.11
Low
8.57
Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company discovers develops and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers develops and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies including multiple myeloma endometrial cancer myelofibrosis and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms as well as verdinexor KPT-9274 and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor eltanexor and KPT-9274 for the treatment and/or prevention of human oncology indications as well as verdinexor for the diagnosis treatment and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton Massachusetts.
View LessKPTI | US
Risk
100.2
Sharpe
0.39
Luna's Score
48/100
Recommendation
Hold
Luna says (KPTI | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
50.3%1 month
100.2%3 months
84.4%6 months
84.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
12.05
Debt to equity
-1.48
Debt to assets
0.91
Ent. to EBITDA
-1.85
Ent. to rev.
1.04
PEG
-0.15
Other Fundamentals
EBITDA
-130.61M
MarketCap
1.09B
MarketCap(USD)
1.09B
Div. yield
-
Op. margin
-65.72
Erngs. growth
-
Rev. growth
13.90
Ret. on equity
-891.05
Short ratio
28.47
Short perc.
15.21
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.42
Range1M
5.09
Range3M
5.29
Volumes: Market Activity
Rel. volume
0.94
Price X volume
6.36M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.85 | 24.85 | Cheaper |
| Ent. to Revenue | 1.04 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 12.05 | 13.15 | Par |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 84.38 | 65.24 | Riskier |
| Debt to Equity | -1.48 | -1.88 | Expensive |
| Debt to Assets | 0.91 | 0.48 | Expensive |
| Market Cap | 1.09B | 3.71B | Emerging |
